Subcutaneous tocilizumab in adults with severe and critical COVID-19 : A prospective open-label uncontrolled multicenter trial
Copyright © 2020. Published by Elsevier B.V..
Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise antiviral and immunomodulatory agents; however, no immunomodulator drug has been approved. This multicenter, prospective, open-label, uncontrolled study aimed to assess the use of subcutaneous tocilizumab in adult patients with severe and critical COVID-19. Tocilizumab was added to the standard care of therapy at a dose of 324 mg (<100 kg bodyweight) or 486 mg (≥100 kg bodyweight). The study endpoints were all-cause mortality rate, changes in oxygen-support level, oxygen saturation, body temperature, respiratory rate, and laboratory variables during the study, and drug safety. Of 126 patients enrolled, 86 had severe and 40 had critical disease. Most patients were male (63.49%) and aged below 65 (78.57%). By day 14 of the study, 4.65% (4/86) of severe patients and 50.00% (20/40) of critical patients died. By the end, 6.98% (6/86) of severe patients and 60.00% (24/40) of critical patients died.Outcomes concerning three additional endpoints (oral temperature, oxygen saturation, and respiratory rate)were significantly improved as early as three days after tocilizumab administration in both groups of subjects, more considerably in severe patients. Significant improvement in the required level of oxygenation was reported in severe patients seven days after tocilizumab administration. No tocilizumab-related serious adverse event occurred in this study. Subcutaneous tocilizumab might improve some clinical parameters and reduce the risk of death in COVID-19 patients, particularly if used in the early stages of respiratory failure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:89 |
|---|---|
| Enthalten in: |
International immunopharmacology - 89(2020), Pt B vom: 02. Dez., Seite 107102 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Malekzadeh, Reza [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 15.12.2020 Date Revised 12.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2020.107102 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316450499 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316450499 | ||
| 003 | DE-627 | ||
| 005 | 20231225161117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2020.107102 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316450499 | ||
| 035 | |a (NLM)33075713 | ||
| 035 | |a (PII)S1567-5769(20)32919-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Malekzadeh, Reza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Subcutaneous tocilizumab in adults with severe and critical COVID-19 |b A prospective open-label uncontrolled multicenter trial |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2020 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier B.V. | ||
| 520 | |a Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise antiviral and immunomodulatory agents; however, no immunomodulator drug has been approved. This multicenter, prospective, open-label, uncontrolled study aimed to assess the use of subcutaneous tocilizumab in adult patients with severe and critical COVID-19. Tocilizumab was added to the standard care of therapy at a dose of 324 mg (<100 kg bodyweight) or 486 mg (≥100 kg bodyweight). The study endpoints were all-cause mortality rate, changes in oxygen-support level, oxygen saturation, body temperature, respiratory rate, and laboratory variables during the study, and drug safety. Of 126 patients enrolled, 86 had severe and 40 had critical disease. Most patients were male (63.49%) and aged below 65 (78.57%). By day 14 of the study, 4.65% (4/86) of severe patients and 50.00% (20/40) of critical patients died. By the end, 6.98% (6/86) of severe patients and 60.00% (24/40) of critical patients died.Outcomes concerning three additional endpoints (oral temperature, oxygen saturation, and respiratory rate)were significantly improved as early as three days after tocilizumab administration in both groups of subjects, more considerably in severe patients. Significant improvement in the required level of oxygenation was reported in severe patients seven days after tocilizumab administration. No tocilizumab-related serious adverse event occurred in this study. Subcutaneous tocilizumab might improve some clinical parameters and reduce the risk of death in COVID-19 patients, particularly if used in the early stages of respiratory failure | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 pandemic | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Interleukin 6 | |
| 650 | 4 | |a Multicenter trial | |
| 650 | 4 | |a Tocilizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Abedini, Atefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Mohsenpour, Behzad |e verfasserin |4 aut | |
| 700 | 1 | |a Sharifipour, Ehsan |e verfasserin |4 aut | |
| 700 | 1 | |a Ghasemian, Roya |e verfasserin |4 aut | |
| 700 | 1 | |a Javad-Mousavi, Seyed Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Khodashahi, Rozita |e verfasserin |4 aut | |
| 700 | 1 | |a Darban, Mahboobeh |e verfasserin |4 aut | |
| 700 | 1 | |a Kalantari, Saeed |e verfasserin |4 aut | |
| 700 | 1 | |a Abdollahi, Nafiseh |e verfasserin |4 aut | |
| 700 | 1 | |a Salehi, Mohammad Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei Hosseinabadi, Abbas |e verfasserin |4 aut | |
| 700 | 1 | |a Khorvash, Farzin |e verfasserin |4 aut | |
| 700 | 1 | |a Valizadeh, Melika |e verfasserin |4 aut | |
| 700 | 1 | |a Dastan, Farzaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Yousefian, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Hamed |e verfasserin |4 aut | |
| 700 | 1 | |a Anjidani, Nassim |e verfasserin |4 aut | |
| 700 | 1 | |a Tabarsi, Payam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 89(2020), Pt B vom: 02. Dez., Seite 107102 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:89 |g year:2020 |g number:Pt B |g day:02 |g month:12 |g pages:107102 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2020.107102 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 89 |j 2020 |e Pt B |b 02 |c 12 |h 107102 | ||